<DOC>
	<DOCNO>NCT00611624</DOCNO>
	<brief_summary>The purpose study determine Mammosite Catheter optimization use multiple dwell position delivery decrease skin toxicity historically report skin toxicity single dwell delivery method .</brief_summary>
	<brief_title>Mammosite Breast Brachytherapy Optimization Treatment Breast Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<criteria>The patient must consent study must sign approve consent form conform institutional guideline . Patient must &gt; 50 year old . The patient life expectancy least two year . The patient must stage 0 , I , II breast cancer . If stage IIA , tumor size must 3 cm less patient must node negative . On histological examination , tumor must DCIS invasive adenocarcinoma breast . Surgical treatment breast must lumpectomy . The margin resect specimen must histologically free tumor ( &gt; 2mm , DCIS invasive ) . Reexcision surgical margin permit . Gross disease must unifocal pathologic ( invasive and/or DCIS ) tumor size 3 cm less . ( Patients microscopic multifocality eligible long total pathologic tumor size 3 cm less . ) Patients invasive breast cancer require axillary stag include sentinel node biopsy alone ( negative ) , sentinel node biopsy follow axillary dissection sample minimum total 6 axillary node axillary dissection alone ( minimum 6 axillary node ) . ( Axillary stag NOT required patient DCIS . ) The patient must MammoSite catheter place within 4 week 28 day final surgery breast cancer ( lumpectomy , reexcision margin , axillary staging procedure ) . Placement spacer MammoSite catheter permit final surgery . Patients history nonipsilateral breast malignancy eligible diseasefree 2 year prior randomization . Patients follow cancer eligible even diagnose treat within past 2 year : carcinoma situ cervix , colon , melanoma situ , basal cell squamous cell carcinoma skin . Patients prior diagnosis ipsilateral breast cancer ineligible . Chemotherapy permit plan &gt; 2 week removal Mammosite catheter . Patient must ineligible refused enrollment randomize trial RTOG ( Radiation Therapy Oncology Group ) 0413 . Men eligible study . T2 ( &gt; 3.0 cm ) , T3 , node positive , stage III IV breast cancer . Any positive axillary node . Palpable radiographically suspicious ipsilateral contralateral axillary , supraclavicular , infraclavicular internal mammary node , unless biopsy proven negative tumor . Suspicious microcalcifications , density palpable abnormality either breast unless biopsy proven benign . Nonepithelial breast malignancy sarcoma lymphoma . Proven multicentric carcinoma one quadrant separate 3 centimeter . Paget 's disease nipple . History invasive breast cancer DCIS breast . Surgical margin microscopically assess less 2 mm . Collagen vascular disease , specifically dermatomyositis creatine phosphokinase ( CPK ) level normal active skin rash , systemic lupus erythematosis scleroderma . Pregnancy lactation time propose radiation . Women reproductive potential must agree use effective nonhormonal method contraception therapy . Psychiatric addictive disorder condition , opinion investigator , would preclude patient meeting study requirement . Patients coexist medical condition life expectancy &lt; 2 year . Patients skin involvement , regardless tumor size . Patients treatment MammoSite catheter feasible , little breast tissue skin catheter ( determined distance dose calculation ) .</criteria>
	<gender>Female</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>MammoSite</keyword>
	<keyword>brachytherapy</keyword>
</DOC>